Sleeping sickness – human African trypanosomiasis

INTRODUCTION One of the great advantages of working with veterinary colleagues is the insight they often bring to the pathogenesis of human disease through their studies of natural animal diseases and animal models. In 1988 Professor Max Murray of the University of Glasgow Veterinary School introduced me to the problem of African trypanosomiasis in animals, its close relationship to its human counterpart that is known as sleeping sickness, and the unsolved problems of neurological involvement in that condition. We have now been investigating the neuropathogenesis of human African trypanosomiasis (HAT) in the laboratory and the African field for the last 16 years (Fig. 1). Neurologists will realize of course that HAT is not to be confused with the other ‘sleeping sickness’ known as encephalitis lethargica, famous for the pandemic during the first quarter of the 20th century, and which still occurs sporadically. While the cause of the latter disease has

[1]  J. Sternberg,et al.  Nitric oxide and cytokine synthesis in human African trypanosomiasis. , 2001, The Journal of infectious diseases.

[2]  V. Jamonneau,et al.  IgM quantification in the cerebrospinal fluid of sleeping sickness patients by a latex card agglutination test , 2002, Tropical medicine & international health : TM & IH.

[3]  M. P. Hutchinson,et al.  Sleeping sickness in Europeans: a review of 109 cases. , 1966, The Journal of tropical medicine and hygiene.

[4]  P. Kennedy,et al.  Neurological aspects of human African trypanosomiasis , 2000 .

[5]  J. Rodgers,et al.  Sleeping sickness: new drugs from old? [corrected]. , 2002, Lancet.

[6]  G. H. Coombs,et al.  The biology of antigenic variation in African trypanosomes. , 1997 .

[7]  J. Adams,et al.  HUMAN AFRICAN TRYPANOSOMIASIS (T.b. GAMBIENSE): A STUDY OF 16 FATAL CASES OF SLEEPING SICKNESS WITH SOME OBSERVATIONS ON ACUTE REACTIVE ARSENICAL ENCEPHALOPATHY , 1986, Neuropathology and applied neurobiology.

[8]  P. Kennedy The pathogenesis and modulation of the post-treatment reactive encephalopathy in a mouse model of Human African Trypanosomiasis , 1999, Journal of Neuroimmunology.

[9]  J. Donelson,et al.  Antigenic variation and the African trypanosome genome. , 2003, Acta tropica.

[10]  Terry K. Smith,et al.  Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial , 2000, The Lancet.

[11]  I. Löwy The Wellcome Trust illustrated history of tropical diseases , 1997, Medical History.

[12]  K. Kristensson,et al.  Trypanosoma brucei and the nervous system , 1994, Trends in Neurosciences.

[13]  B. Robertson,et al.  Cerebral vessel laminins and IFN-gamma define Trypanosoma brucei brucei penetration of the blood-brain barrier. , 2004, The Journal of clinical investigation.

[14]  T. Niyonsenga,et al.  Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[15]  F. Kuzoe Current situation of African trypanosomiasis. , 1993, Acta tropica.

[16]  J. Baker Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. , 1999, World Health Organization technical report series.

[17]  P. Kennedy,et al.  Human African trypanosomiasis of the CNS: current issues and challenges. , 2004, The Journal of clinical investigation.